Biosensors in clinical practice: focus on oncohematology.

Research output: Contribution to journalArticle

Abstract

Biosensors are devices that are capable of detecting specific biological analytes and converting their presence or concentration into some electrical, thermal, optical or other signal that can be easily analysed. The first biosensor was designed by Clark and Lyons in 1962 as a means of measuring glucose. Since then, much progress has been made and the applications of biosensors are today potentially boundless. This review is limited to their clinical applications, particularly in the field of oncohematology. Biosensors have recently been developed in order to improve the diagnosis and treatment of patients affected by hematological malignancies, such as the biosensor for assessing the in vitro pre-treatment efficacy of cytarabine in acute myeloid leukemia, and the fluorescence resonance energy transfer-based biosensor for assessing the efficacy of imatinib in chronic myeloid leukemia. The review also considers the challenges and future perspectives of biosensors in clinical practice.

Original languageEnglish
Pages (from-to)6423-6447
Number of pages25
JournalSensors (Switzerland)
Volume13
Issue number5
Publication statusPublished - 2013

Fingerprint

Biosensing Techniques
bioinstrumentation
Biosensors
leukemias
Fluorescence Resonance Energy Transfer
Cytarabine
Hematologic Neoplasms
resonance fluorescence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Myeloid Leukemia
glucose
pretreatment
Glucose
optical communication
Hot Temperature
energy transfer
Equipment and Supplies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biosensors in clinical practice : focus on oncohematology. / Fracchiolla, Nicola S.; Artuso, Silvia; Cortelezzi, Agostino.

In: Sensors (Switzerland), Vol. 13, No. 5, 2013, p. 6423-6447.

Research output: Contribution to journalArticle

@article{1a41d2015ce94618b034988799941ac0,
title = "Biosensors in clinical practice: focus on oncohematology.",
abstract = "Biosensors are devices that are capable of detecting specific biological analytes and converting their presence or concentration into some electrical, thermal, optical or other signal that can be easily analysed. The first biosensor was designed by Clark and Lyons in 1962 as a means of measuring glucose. Since then, much progress has been made and the applications of biosensors are today potentially boundless. This review is limited to their clinical applications, particularly in the field of oncohematology. Biosensors have recently been developed in order to improve the diagnosis and treatment of patients affected by hematological malignancies, such as the biosensor for assessing the in vitro pre-treatment efficacy of cytarabine in acute myeloid leukemia, and the fluorescence resonance energy transfer-based biosensor for assessing the efficacy of imatinib in chronic myeloid leukemia. The review also considers the challenges and future perspectives of biosensors in clinical practice.",
author = "Fracchiolla, {Nicola S.} and Silvia Artuso and Agostino Cortelezzi",
year = "2013",
language = "English",
volume = "13",
pages = "6423--6447",
journal = "Sensors",
issn = "1424-3210",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Biosensors in clinical practice

T2 - focus on oncohematology.

AU - Fracchiolla, Nicola S.

AU - Artuso, Silvia

AU - Cortelezzi, Agostino

PY - 2013

Y1 - 2013

N2 - Biosensors are devices that are capable of detecting specific biological analytes and converting their presence or concentration into some electrical, thermal, optical or other signal that can be easily analysed. The first biosensor was designed by Clark and Lyons in 1962 as a means of measuring glucose. Since then, much progress has been made and the applications of biosensors are today potentially boundless. This review is limited to their clinical applications, particularly in the field of oncohematology. Biosensors have recently been developed in order to improve the diagnosis and treatment of patients affected by hematological malignancies, such as the biosensor for assessing the in vitro pre-treatment efficacy of cytarabine in acute myeloid leukemia, and the fluorescence resonance energy transfer-based biosensor for assessing the efficacy of imatinib in chronic myeloid leukemia. The review also considers the challenges and future perspectives of biosensors in clinical practice.

AB - Biosensors are devices that are capable of detecting specific biological analytes and converting their presence or concentration into some electrical, thermal, optical or other signal that can be easily analysed. The first biosensor was designed by Clark and Lyons in 1962 as a means of measuring glucose. Since then, much progress has been made and the applications of biosensors are today potentially boundless. This review is limited to their clinical applications, particularly in the field of oncohematology. Biosensors have recently been developed in order to improve the diagnosis and treatment of patients affected by hematological malignancies, such as the biosensor for assessing the in vitro pre-treatment efficacy of cytarabine in acute myeloid leukemia, and the fluorescence resonance energy transfer-based biosensor for assessing the efficacy of imatinib in chronic myeloid leukemia. The review also considers the challenges and future perspectives of biosensors in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84891699793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891699793&partnerID=8YFLogxK

M3 - Article

C2 - 23673681

VL - 13

SP - 6423

EP - 6447

JO - Sensors

JF - Sensors

SN - 1424-3210

IS - 5

ER -